



CorInnova has developed a **minimally invasively-delivered soft robotic heart device**, the world's first, to support heart function for treatment of Heart Failure (HF). EpicHeart™ is designed to eliminate 40% of the adverse events associated with FDA-cleared left ventricular assist devices (LVADs) and promises to promote heart recovery.

❑ **FIRST PRACTICAL SOFT ROBOTIC DEVICE FOR HEART FUNCTION SUPPORT.** One million U.S. and E.U. patients with end-stage Heart Failure have an extremely poor prognosis (40% two-year mortality), and treatment options are limited. Transplant is the preferred treatment because drug therapies are largely ineffective, but only about 4,500 hearts are available worldwide. Increasingly, left ventricular assist devices (LVADs) are used to prolong life, but the devices require invasive surgery and contact the blood, risking blood clots and stroke as well as bleeding from necessary anti-coagulant therapy. LVAD failure can cause blood clots and patient death. And, LVADs and other treatments are focused on *treating symptoms* rather than *recovery*, so mortality is high.

❑ **DISRUPTIVE “NON-BLOOD-CONTACTING” TECHNOLOGY.** CorInnova's device, **EpicHEART™**, is a breakthrough medical technology advancement. It is delivered minimally invasively, reducing hospital length of stay. The device does not contact the blood, eliminating risk of thrombosis and stroke, the need for anticoagulants, and the risk of bleeding. It is **biventricular**, so it also is designed to treat those 15%+ of LVAD patients who develop **right** ventricular heart failure (RVHF). Moreover, device operation is non-obligatory, so the EpicHEART device is designed to be turned off safely without harming the patient. Overall, adverse events could be reduced 40%+ versus the best LVADs.

❑ **RIGHT STRATEGY TO BREACH ENORMOUS MARKET OPPORTUNITY.** According to the **Global Left Ventricular Assist Device (LVAD) Market 2016-2020**, the worldwide market for LVADs is projected to grow at a CAGR of 13.19% during the period 2016 through 2020, reaching sales of more than \$1 billion. The research report identifies the “key players” in the global left ventricular assist device (LVAD) market as Abiomed, Berlin Heart, HeartWare International, Jarvik Heart, and St. Jude Medical. CorInnova's less-invasive EpicHEART device could potentially increase eligible patients by 4X, thus quadrupling the market to \$4+ billion.

❑ **WORLD CLASS LEADERSHIP TEAM.** CEO William Altman is a Rhodes scholar, Harvard MBA, ex-McKinsey consultant, and successful serial entrepreneur. His team is exceptional, including: the former SVP and Chief Regulatory Officer for Medtronic who also served as the FDA's Director of the Office of Device Evaluation; an investment banker who raised \$1 billion for Lexicon Pharmaceuticals; the inventor of the Thoratec LVAD; a co-inventor of the TAXUS drug-eluting stent; and several KOLs in the field of heart recovery.



“CorInnova's device will revolutionize the treatment of Heart Failure, saving countless lives.”

William Altman
CEO, CorInnova, Inc.;
Rhodes scholar, Harvard MBA,
ex-McKinsey consultant,
successful serial entrepreneur.



“CorInnova's device does not contact blood, eliminating risk of thrombosis and stroke, and need for anti-coagulants.”

Boris Leschinsky
VP, Product Development CorInnova, Inc.
Cardiac assist device authority;
inventor of the Thoratec PHP
next-gen LVAD.

CONTACTS & KEY INFORMATION

Headquarters	2450 Holcombe Blvd., Suite J Houston, TX 77021 (713) 530-1430
Website	www.corinnova.com
Ownership	Privately held
Funding	\$8.5 Million
Sector	Cardiac Assist Devices
Platform	EpicHeart™ (preclinical)
Mechanism	Collapsible thin-film pneumatically actuated soft robotic device that surrounds both ventricles of the heart; air inflates the device in synchrony with the heart and increases cardiac output by gently squeezing the heart.
PR Agency Contact	Ronald Trahan, APR Ronald Trahan Associates, Inc. +1 508-359-4005, ext. 108

LEADERSHIP TEAM AND ADVISERS

William Altman Chief Executive Officer
John Criscione, M.D., Ph.D. Founder, Chief Technical Officer
Boris Leschinsky VP, Product Dev; Inventor Thoratec PHP LVAD
Clarice Motter Chief Financial Officer
Keith Svagerko VP, Administration & Business Development
Dan Burkhoff, M.D., PhD. Columbia University School of Medicine
William Abraham, M.D. Ohio State University School of Medicine
William Hunter, M.D. Co-inventor of TAXUS drug-eluting stent
Ulrich Jorde, M.D. NY Presbyterian-Columbia Univ. Medical Center
Dan Meyer M.D. Univ. of Texas Southwestern Medical Center
Susan Alpert, M.D., Ph.D. Fmr. Director, FDA Office of Device Evaluation
Biswajit Kar, M.D. Dir., Ctr. for Advanced HF, UT Health Science Ctr.
Julie Gregory Investment banker; raised \$1B Lexicon Pharma